Rosacea fulminans related to pegylated interferon alpha-2b and ribavirin therapy.
Bettoli
Vincenzo
V
Mantovani
Lucia
L
Boccia
Sergio
S
Virgili
Annarosa
A
D000284:Administration, Oral; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005148:Facial Dermatoses / Q000139:chemically induced / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D007267:Injections; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*; D012393:Rosacea / Q000139:chemically induced / Q000175:diagnosis* / Q000473:pathology
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b